Compare Bristol-Myers Squibb Co (BMY) vs Datadog Inc (DDOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Datadog Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.6 (market cap $129.94B), while Datadog Inc trades at $243.42 (market cap $88.61B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Datadog Inc pays none. Which is the better fit depends on your goals.
| BMY | DDOG | |
|---|---|---|
Market Cap | $129.94B | $88.61B |
Sector | Health | Technology |
52-Week High | $65.89 | $288.15 |
52-Week Low | $42.60 | $102.62 |
Enterprise Value | $163.92B | $84.90B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Datadog (DDOG) trades at $260.78, up 11.48% in 24 hours, reflecting strong momentum after Q2 2026 earnings beat expectations with EPS of $0.65 versus $0.583 estimated. Revenue grew 36% year-over-year, and the company raised full-year 2026 guidance. Technical indicators show a bullish trend with support at $239 and resistance at $272, while high valuation multiples like a P/E of 493.56 signal premium pricing. Recent news highlights AI-driven growth but also insider selling and market sensitivity to guidance nuances.
The outlook remains positive due to robust revenue growth and AI adoption, but risks include elevated valuations and customer concentration. Analyst consensus is strongly bullish with an average price target of $288.55, though investors should monitor execution against high expectations and competitive pressures in the cloud monitoring space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Datadog Inc
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →
